HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 120 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2013. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $61,820,403 | +25.2% | 1,180,680 | -2.8% | 0.01% | +33.3% |
Q1 2024 | $49,393,063 | +3.3% | 1,214,185 | -6.1% | 0.01% | -10.0% |
Q4 2023 | $47,806,873 | -3.9% | 1,293,476 | -0.6% | 0.01% | -9.1% |
Q3 2023 | $49,727,767 | +3.6% | 1,301,774 | -2.2% | 0.01% | +10.0% |
Q2 2023 | $47,995,971 | -9.6% | 1,330,634 | -4.2% | 0.01% | -16.7% |
Q1 2023 | $53,071,537 | -35.2% | 1,389,671 | -3.4% | 0.01% | -36.8% |
Q4 2022 | $81,843,254 | +36.1% | 1,438,370 | -5.5% | 0.02% | +26.7% |
Q3 2022 | $60,152,000 | -11.2% | 1,521,290 | -1.2% | 0.02% | 0.0% |
Q2 2022 | $67,773,000 | +11.2% | 1,540,276 | +0.8% | 0.02% | +25.0% |
Q1 2022 | $60,950,000 | -1.6% | 1,528,313 | -0.8% | 0.01% | +9.1% |
Q4 2021 | $61,936,000 | -3.1% | 1,540,266 | -1.9% | 0.01% | -8.3% |
Q3 2021 | $63,890,000 | -4.8% | 1,570,525 | +6.2% | 0.01% | -7.7% |
Q2 2021 | $67,138,000 | +11.5% | 1,478,487 | +2.4% | 0.01% | +8.3% |
Q1 2021 | $60,199,000 | -4.3% | 1,443,997 | -1.9% | 0.01% | -14.3% |
Q4 2020 | $62,873,000 | +232.7% | 1,472,112 | +104.7% | 0.01% | +180.0% |
Q3 2020 | $18,897,000 | +1.2% | 719,047 | +3.3% | 0.01% | 0.0% |
Q2 2020 | $18,665,000 | +66.6% | 696,208 | +11.8% | 0.01% | +25.0% |
Q1 2020 | $11,206,000 | -2.0% | 622,892 | -3.4% | 0.00% | +33.3% |
Q4 2019 | $11,430,000 | +14.5% | 644,701 | +0.2% | 0.00% | 0.0% |
Q3 2019 | $9,981,000 | -12.1% | 643,467 | -2.6% | 0.00% | 0.0% |
Q2 2019 | $11,355,000 | +9.8% | 660,904 | +2.9% | 0.00% | 0.0% |
Q1 2019 | $10,338,000 | +6.8% | 642,167 | -3.0% | 0.00% | 0.0% |
Q4 2018 | $9,684,000 | -68.6% | 661,883 | -60.9% | 0.00% | -62.5% |
Q3 2018 | $30,794,000 | +7.0% | 1,694,777 | -0.7% | 0.01% | 0.0% |
Q2 2018 | $28,786,000 | -14.3% | 1,706,318 | -0.5% | 0.01% | -11.1% |
Q1 2018 | $33,596,000 | -10.7% | 1,714,960 | -7.7% | 0.01% | -10.0% |
Q4 2017 | $37,626,000 | +3.2% | 1,857,114 | -11.5% | 0.01% | 0.0% |
Q3 2017 | $36,462,000 | +52.8% | 2,099,164 | +12.8% | 0.01% | +42.9% |
Q2 2017 | $23,866,000 | +1.9% | 1,861,571 | +3.0% | 0.01% | +16.7% |
Q1 2017 | $23,412,000 | +67.0% | 1,806,490 | +27.3% | 0.01% | +50.0% |
Q4 2016 | $14,020,000 | -32.6% | 1,419,004 | -17.6% | 0.00% | -33.3% |
Q3 2016 | $20,808,000 | +5.8% | 1,722,504 | -24.4% | 0.01% | 0.0% |
Q2 2016 | $19,674,000 | +318.2% | 2,279,701 | +359.0% | 0.01% | +500.0% |
Q1 2016 | $4,704,000 | -84.8% | 496,634 | -72.2% | 0.00% | -88.9% |
Q4 2015 | $31,003,000 | +356.0% | 1,788,946 | +253.4% | 0.01% | +350.0% |
Q3 2015 | $6,799,000 | -53.6% | 506,171 | -21.9% | 0.00% | -50.0% |
Q2 2015 | $14,643,000 | +64.8% | 648,452 | +4.2% | 0.00% | +100.0% |
Q1 2015 | $8,884,000 | +68.5% | 622,210 | +13.9% | 0.00% | +100.0% |
Q4 2014 | $5,273,000 | +6.5% | 546,438 | +0.5% | 0.00% | 0.0% |
Q3 2014 | $4,949,000 | -49.8% | 543,772 | -45.5% | 0.00% | 0.0% |
Q2 2014 | $9,860,000 | +63.1% | 998,050 | +109.8% | 0.00% | -50.0% |
Q1 2014 | $6,044,000 | -10.5% | 475,779 | +5.6% | 0.00% | 0.0% |
Q4 2013 | $6,755,000 | -31.7% | 450,610 | -49.7% | 0.00% | +100.0% |
Q3 2013 | $9,886,000 | +181.4% | 895,508 | +102.6% | 0.00% | 0.0% |
Q2 2013 | $3,513,000 | – | 441,982 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |